Type Whole antibody Target CD274 CAS Number 1428935-60-7 | Source Human ATC code none IUPHAR/BPS 7985 | |
Durvalumab is a monoclonal antibody being investigated for the treatment of cancer. It targets programmed death ligand-1 (PD-L1).
This drug was developed by MedImmune.
Clinical trials
A phase 1B clinical trial of durvalumab and tremelimumab showed some activity in non-small cell lung cancer (NSCLC).
Phase 1 data in advanced metastatic urothelial bladder (Study 1108) has led to FDA breakthrough therapy designation.
Early results of a phase I trial combining durvalumab and gefitinib in lung cancer patients "showed promise".
References
Durvalumab Wikipedia(Text) CC BY-SA